Sunshine Biopharma (SBFM) Competitors $2.78 -0.02 (-0.71%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SBFM vs. MRNS, PMCB, SLGL, WENA, AWH, IPA, IMNN, RLMD, CRVO, and KZIAShould you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Marinus Pharmaceuticals (MRNS), PharmaCyte Biotech (PMCB), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), Aspira Women's Health (AWH), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), Relmada Therapeutics (RLMD), CervoMed (CRVO), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical products" industry. Sunshine Biopharma vs. Marinus Pharmaceuticals PharmaCyte Biotech Sol-Gel Technologies ANEW Medical Aspira Women's Health ImmunoPrecise Antibodies Imunon Relmada Therapeutics CervoMed Kazia Therapeutics Marinus Pharmaceuticals (NASDAQ:MRNS) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation. Does the media refer more to MRNS or SBFM? In the previous week, Marinus Pharmaceuticals had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 1 mentions for Marinus Pharmaceuticals and 0 mentions for Sunshine Biopharma. Marinus Pharmaceuticals' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score. Company Overall Sentiment Marinus Pharmaceuticals Neutral Sunshine Biopharma Neutral Do analysts prefer MRNS or SBFM? Marinus Pharmaceuticals currently has a consensus price target of $4.79, suggesting a potential upside of 1,980.75%. Sunshine Biopharma has a consensus price target of $15.00, suggesting a potential upside of 439.57%. Given Marinus Pharmaceuticals' higher possible upside, research analysts clearly believe Marinus Pharmaceuticals is more favorable than Sunshine Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36Sunshine Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, MRNS or SBFM? Sunshine Biopharma has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarinus Pharmaceuticals$30.99M0.41-$141.40M-$2.47-0.09Sunshine Biopharma$32.96M0.10-$4.51M-$150.88-0.02 Is MRNS or SBFM more profitable? Sunshine Biopharma has a net margin of -12.82% compared to Marinus Pharmaceuticals' net margin of -446.48%. Sunshine Biopharma's return on equity of -17.89% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Marinus Pharmaceuticals-446.48% -7,831.35% -120.74% Sunshine Biopharma -12.82%-17.89%-14.25% Do institutionals and insiders believe in MRNS or SBFM? 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 5.5% of Marinus Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MRNS or SBFM? Marinus Pharmaceuticals received 435 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 67.54% of users gave Marinus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMarinus PharmaceuticalsOutperform Votes43767.54% Underperform Votes21032.46% Sunshine BiopharmaOutperform Votes2100.00% Underperform VotesNo Votes Which has more risk & volatility, MRNS or SBFM? Marinus Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. SummaryMarinus Pharmaceuticals and Sunshine Biopharma tied by winning 9 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.So please click here to see the details because a lot of people could get rich. Get Sunshine Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBFM vs. The Competition Export to ExcelMetricSunshine BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.40M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.0210.4689.5817.17Price / Sales0.10195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.005.094.774.78Net Income-$4.51M$151.83M$120.15M$225.60M7 Day Performance1.09%-2.13%-1.92%-1.23%1 Month Performance31.13%-3.10%11.47%3.36%1 Year Performance-89.10%11.54%30.52%16.60% Sunshine Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBFMSunshine Biopharma1.3441 of 5 stars$2.78-0.7%$15.00+439.6%-89.1%$3.40M$32.96M-0.023MRNSMarinus Pharmaceuticals4.3176 of 5 stars$0.23-11.2%$4.79+1,950.4%-97.6%$12.88M$31.47M-0.10110Analyst ForecastNews CoveragePMCBPharmaCyte Biotech0.4217 of 5 stars$1.67-2.9%N/A-24.8%$12.83MN/A2.612Earnings ReportSLGLSol-Gel Technologies2.4245 of 5 stars$0.46-4.1%$5.00+987.2%-66.5%$12.81M$1.55M-1.3650WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpAWHAspira Women's Health1.218 of 5 stars$0.74-0.8%$4.40+491.7%-69.7%$12.40M$9.15M-0.62110Analyst ForecastIPAImmunoPrecise Antibodies2.9227 of 5 stars$0.43+6.6%$5.00+1,063.1%-69.5%$12.40M$24.07M-0.5280News CoverageIMNNImunon2.3546 of 5 stars$0.84-0.5%$20.50+2,338.7%+9.2%$12.19M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpRLMDRelmada Therapeutics4.19 of 5 stars$0.40+8.4%$4.25+967.8%-87.7%$12.01MN/A-0.1310Gap DownHigh Trading VolumeCRVOCervoMed2.1768 of 5 stars$1.94+2.1%$42.00+2,065.1%-67.1%$11.97M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeKZIAKazia Therapeutics1.7318 of 5 stars$3.58+0.8%$20.00+458.7%-21.6%$11.92M$2.31M0.0012Gap Up Related Companies and Tools Related Companies MRNS Competitors PMCB Competitors SLGL Competitors WENA Competitors AWH Competitors IPA Competitors IMNN Competitors RLMD Competitors CRVO Competitors KZIA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SBFM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBFM Stock Alerts